News

Zimmer has said that it expects to fund the purchase price from cash on hand and borrowings under existing credit facilities. The acquisition is expected to close in

Celator is currently preparing to conduct two randomized Phase II studies with CPX-351. The first Phase II study, in newly diagnosed, elderly patients with acute myeloid leukemia (AML)

The glioblastoma multiforme (GBM) clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite

Jeffrey Burbank, president and CEO of NxStage Medical, said: “We are very pleased to affirm our long-standing relationship as DaVita’s preferred bloodline vendor. “This contract demonstrates both the

The announcement came on the heels of FDA’s clearance for the Pathwork Tissue of Origin test for diagnosis of tumors of uncertain origin, including poorly differentiated, undifferentiated and

Bilcare Global Clinical Supplies’s (GCS) latest Phase III investments include the upgrade of its Kalish large-scale bottling line at its US facility and an investment in new Pentapack

Amrubicin is a third-generation, synthetic anthracycline analogue that has demonstrated substantial clinical efficacy in the treatment of small cell lung cancer. Amrubicin has been granted orphan-drug designation for

Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of

Dirucotide (MBP8298) is currently being evaluated in a US pivotal Phase III trial, named Maestro-03, at 68 sites with approximately 510 patients. Kevin Giese, president and CEO of